A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults

References

• Messina JP, Brady OJ, Golding N, Kraemer MUG, Wint GRW, Ray SE, Pigott DM, Shearer FM, Johnson K, Earl L, et al. The current and future global distribution and population at risk of dengue. Nat Microbiol. 2019;4(9):1508–12. doi:10.1038/s41564-019-0476-8.
   PubMed Web of Science ®Google Scholar
• Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes CL, Farlow AW, Scott TW, Hay SI. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis. 2012;6(8):e1760. doi:10.1371/journal.pntd.0001760.
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. Lancet. 2019;393(10169):350–63. doi:10.1016/s0140-6736(18)32560-1.
   PubMed Web of Science ®Google Scholar
• Cattarino L, Rodriguez-Barraquer I, Imai N, Cummings DAT, Ferguson NM. Mapping global variation in dengue transmission intensity. Sci Transl Med. 2020;12(528). doi:10.1126/scitranslmed.aax4144.
   PubMed Web of Science ®Google Scholar
• Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, Hay SI, Bedi N, Bensenor IM, Castaneda-Orjuela CA, et al. The global burden of dengue: an analysis from the global burden of disease study 2013. Lancet Infect Dis. 2016;16(6):712–23. doi:10.1016/s1473-3099(16)00026-8.
   PubMed Web of Science ®Google Scholar
• Gubler DJ, Meltzer M. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv Virus Res. 1999:5335–70. doi:10.1016/s0065-3527(08)60342-5.
   Web of Science ®Google Scholar
• Gibbons RV, Kalanarooj S, Jarman RG, Nisalak A, Vaughn DW, Endy TP, Mammen MP Jr., Srikiatkhachorn A. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg. 2007;77(5):910–13. doi:10.4269/ajtmh.2007.77.910. PMID: 17984352.
   PubMed Web of Science ®Google Scholar
• Reich NG, Shrestha S, King AA, Rohani P, Lessler J, Kalayanarooj S, Yoon IK, Gibbons RV, Burke DS, Cummings DA. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc Interface. 2013;10(86):20130414. doi:10.1098/rsif.2013.0414.
   PubMed Web of Science ®Google Scholar
• Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, Kuan G, Gordon A, Balmaseda A, Harris E. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis. 2013;7(8):e2357. doi:10.1371/journal.pntd.0002357.
   PubMed Web of Science ®Google Scholar
• Anderson KB, Gibbons RV, Cummings DA, Nisalak A, Green S, Libraty DH, Jarman RG, Srikiatkhachorn A, Mammen MP, Darunee B, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis. 2014;209(3):360–68. doi:10.1093/infdis/jit436.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Dengue antibody-dependent enhancement: Knowns and unknowns. Microbiol Spectr. 2014;2(6). doi:10.1128/microbiolspec.AID-0022-2014.
   PubMedGoogle Scholar
• Halstead SB. Safety issues from a phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine. Hum Vaccin Immunother. 2018;14(9):2158–62. doi:10.1080/21645515.2018.1445448.
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195–206. doi:10.1056/NEJMoa1506223.
   PubMed Web of Science ®Google Scholar
• Gailhardou S, Skipetrova A, Dayan GH, Jezorwski J, Saville M, Van der Vliet D, Wartel TA. Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: pooled analysis of data from 18 clinical trials. PLoS Negl Trop Dis. 2016;10(7):e0004821. doi:10.1371/journal.pntd.0004821.
   PubMed Web of Science ®Google Scholar
• Dengue vaccine: WHO position paper-September 2018. World Health Organization Weekly Epidemiological Record. Dengue vaccines: WHO position paper – September 2018; 2018 [accessed 2022 Feb 16]. p. 457–76.
   Google Scholar
• Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis. 2015;212(5):702–10. doi:10.1093/infdis/jiv082.
   PubMed Web of Science ®Google Scholar
• Durbin AP, Kirkpatrick BD, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Opert K, Jarvis AP, Sabundayo BP, et al. A 12-month-interval dosing study in adults indicates that a single dose of the national institute of allergy and infectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response. J Infect Dis. 2016;214(6):832–35. doi:10.1093/infdis/jiw067.
   PubMedGoogle Scholar
• Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg. 2001;65(5):405–13. doi:10.4269/ajtmh.2001.65.405.
   PubMed Web of Science ®Google Scholar
• Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: A randomized, double-blind clinical trial. J Infect Dis. 2013;207(6):957–65. doi:10.1093/infdis/jis936.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, Larsson CJ, Sabundayo BP, Talaat KR, Janiak A, et al. The live attenuated dengue vaccine tv003 elicits complete protection against dengue in a human challenge model. Sci Transl Med. 2016;8(330):330ra336. doi:10.1126/scitranslmed.aaf1517.
   Web of Science ®Google Scholar
• Whitehead SS, Durbin AP, Pierce KK, Elwood D, McElvany BD, Fraser EA, Carmolli MP, Tibery CM, Hynes NA, Jo M, et al. In a randomized trial, the live attenuated tetravalent dengue vaccine tv003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl Trop Dis. 2017;11(5):e0005584. doi:10.1371/journal.pntd.0005584.
   PubMed Web of Science ®Google Scholar
• Kallas EG, Precioso AR, Palacios R, Thomé B, Braga PE, Vanni T, Campos LMA, Ferrari L, Mondini G, da graça Salomão M, et al. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine butantan-dv in adults in brazil: A two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet Infect Dis. 2020;20(7):839–50. doi:10.1016/s1473-3099(20)30023-2.
   PubMed Web of Science ®Google Scholar
• Blaney JE Jr., Durbin AP, Murphy BR, Whitehead SS. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol. 2006;19(1):10–32. doi:10.1089/vim.2006.19.10.
   PubMed Web of Science ®Google Scholar
• Whiteman MC, Bogardus L, Giacone DG, Rubinstein LJ, Antonello JM, Sun D, Daijogo S, Gurney KB. Virus reduction neutralization test: A single-cell imaging high-throughput virus neutralization assay for dengue. Am J Trop Med Hyg. 2018;99(6):1430–39. doi:10.4269/ajtmh.17-0948.
   PubMed Web of Science ®Google Scholar
• Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventative vaccine clinical trials. 2007 [accessed 2022 Feb 16]. http://www.fda.gov/cber/guidelines.htm.
   Google Scholar
• Katzelnick LC, Harris E. Immune correlates of protection for dengue: State of the art and research agenda. Vaccine. 2017;35(36):4659–69. doi:10.1016/j.vaccine.2017.07.045.
   PubMed Web of Science ®Google Scholar
• Nivarthi UK, Swanstrom J, Delacruz MJ, Patel B, Durbin AP, Whitehead SS, Kirkpatrick BD, Pierce KK, Diehl SA, Katzelnick L, et al. A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans. Nat Commun. 2021;12(1):1102. doi:10.1038/s41467-021-21384-0.
   PubMed Web of Science ®Google Scholar
• Rupp R, Luckasen GJ, Kirstein JL, Osorio JE, Santangelo JD, Raanan M, Smith MK, Wallace D, Gordon GS, Stinchcomb DT. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (tdv) in healthy adults: A phase 1b randomized study. Vaccine. 2015;33(46):6351–59. doi:10.1016/j.vaccine.2015.09.008.
   PubMed Web of Science ®Google Scholar
• Dayan GH, Thakur M, Boaz M, Johnson C. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. Vaccine. 2013;31(44):5047–54. doi:10.1016/j.vaccine.2013.08.088.
   PubMed Web of Science ®Google Scholar
• Biswal S, Borja-Tabora C, Martinez Vargas L, Velásquez H, Theresa Alera M, Sierra V, Johana Rodriguez-Arenales E, Yu D, Wickramasinghe VP, Duarte Moreira E, et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: A randomised, placebo-controlled, phase 3 trial. Lancet. 2020;395(10234):1423–33. doi:10.1016/s0140-6736(20)30414-1.
   PubMed Web of Science ®Google Scholar
• Dayan GH, Langevin E, Gilbert PB, Wu Y, Moodie Z, Forrat R, Price B, Frago C, Bouckenooghe A, Cortes M, et al. Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus. Vaccine. 2020;38(19):3531–36. doi:10.1016/j.vaccine.2020.03.029.
   PubMed Web of Science ®Google Scholar
• Durbin AP. Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate tv003/tv005. Curr Opin Virol. 2020:4379–87. doi:10.1016/j.coviro.2020.09.005.
   Web of Science ®Google Scholar
• Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL, Sun W. Phase i trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg. 2003;69(6 Suppl):48–60. doi:10.4269/ajtmh.2003.69.48.
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chambonneau L, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J. 2004;23(2):99–109. doi:10.1097/01.inf.0000109289.55856.27.
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Angelo MA, Bangs DJ, Sidney J, Paul S, Peters B, de Silva AD, Lindow JC, Diehl SA, Whitehead S, et al. The human cd8+ t cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol. 2015;89(1):120–28. doi:10.1128/JVI.02129-14.
   PubMed Web of Science ®Google Scholar
• Tu HA, Nivarthi UK, Graham NR, Eisenhauer P, Delacruz MJ, Pierce KK, Whitehead SS, Boyson JE, Botten JW, Kirkpatrick BD, et al. Stimulation of b cell immunity in flavivirus-naive individuals by the tetravalent live attenuated dengue vaccine tv003. Cell Rep Med. 2020;1(9):100155. doi:10.1016/j.xcrm.2020.100155.
   PubMedGoogle Scholar